Reporting owner · CIK 0001882764

Hohl Benjamin

Visual SEC Form 4 history across 1 companies, 26 transactions and 7 filings.

CFOCHIEF FINANCIAL OFFICEREnliven Therapeutics, Inc.
Open-market mix
Latest filingSep 21, 2026, 09:23 PM
Filings7Form 4 records
Buying$00 purchases
Selling$992.9K11 sales
Net value−$992.9KBuys minus sells
Companies13 securities
Most recentSep 17, 2026exercise

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-52Dec 231Jan 241Jan 252Feb 252Aug 263Sep 26

Net value flow

Buys minus sells

Dec 23
−$37.5K
Jan 24
−$140.8K
Jan 25
−$70.2K
Feb 25
−$88.9K
Aug 26
−$352.6K
Sep 26
−$303K

Transaction texture

Ownership and ticket size

Average P/S size$90.3K
Median P/S size$70.2K
Direct26
Indirect0
Sep 17, 2026exercise

Filing-only signals

Deterministic matches in this insider's history

Cluster Sellingpattern3Derivative Transactionfiling-context7Direct Ownershipfiling-context21Large Holdings Increaseholdings4Large Holdings Reductionholdings2Large Salesize1Repeat Sellerpattern210b5-1 Detectedfiling-context20

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at Enliven Therapeutics, Inc. on Sep 17, 2026 valued at $14,881.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at Enliven Therapeutics, Inc. on Sep 17, 2026 valued at $14,881.

Review SEC filing

Associated companies

Visual map of known reporting history

ELVNEnliven Therapeutics, Inc.26 transactions · latest Sep 21, 2026, 09:23 PM

Latest insider transactions

Form 4 filings from available history. Click any column to sort; click it again to flip the order.

Hohl Benjamin transactions
IDTickerInsiderRoleTypeSharesValueCodeFiledTrans date
#80262ELVNHohl Benjamin
CFO
grant171k$0A02/10/202502/06/2025
#123739ELVNHohl Benjamin
CFO
exercise10b5-11.00k$0M02/08/202502/05/2025
#123738ELVNHohl Benjamin
CFO
sale10b5-11.00k-$2.25MS02/08/202502/05/2025
#123737ELVNHohl Benjamin
CFO
exercise10b5-11.00k$248kM02/08/202502/05/2025
#59096ELVNHohl Benjamin
CFO
exercise10b5-13.25k$0M01/30/202501/27/2025
#59095ELVNHohl Benjamin
CFO
sale10b5-13.25k-$7.01MS01/30/202501/27/2025
#59094ELVNHohl Benjamin
CFO
exercise10b5-13.25k$806kM01/30/202501/27/2025
#167917ELVNHohl Benjamin
CFO
exercise10b5-19.38k$0M01/02/202401/02/2024
#167915ELVNHohl Benjamin
CFO
exercise10b5-120$0M01/02/202412/29/2023
#167913ELVNHohl Benjamin
CFO
exercise10b5-12.46k$0M01/02/202412/28/2023

Hohl Benjamin Insider Activity FAQ

SEC Form 4 context

Who is Hohl Benjamin?

Hohl Benjamin is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001882764.

Which companies has Hohl Benjamin reported transactions for?

Enliven Therapeutics, Inc.

When was Hohl Benjamin's latest insider buy?

No open-market insider purchase is available for this period.

When was Hohl Benjamin's latest insider sale?

sale at Enliven Therapeutics, Inc. on Sep 17, 2026 valued at $14,881.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.